Advancements in Neoadjuvant Therapy for Melanoma

This chapter explores recent progress in neoadjuvant therapies for stage 3 melanoma, emphasizing the effectiveness of Pembrolizumab in enhancing survival rates and immune response. Key studies are analyzed, comparing the outcomes of neoadjuvant immunotherapy with targeted BRAF MEK inhibitors and discussing the implications for adjuvant therapies in high-risk melanoma patients.